B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 15, Pages 5192
Publisher
MDPI AG
Online
2020-07-23
DOI
10.3390/ijms21155192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- (2020) Chunrui Li et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
- (2020) Talha Badar et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
- (2020) Peter Braendstrup et al. CYTOTHERAPY
- Chimeric antigen receptor T-cell therapy for multiple myeloma
- (2020) Naoki Hosen INTERNATIONAL JOURNAL OF HEMATOLOGY
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
- (2020) Gils Roex et al. Pharmaceutics
- Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
- (2020) Mehmet Soy et al. CLINICAL RHEUMATOLOGY
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
- (2020) Ajay K. Nooka et al. JOURNAL OF CLINICAL ONCOLOGY
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Single-Chain Variable Fragment-based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
- (2019) Raoufeh Ahamadi-Fesharaki et al. Molecular Therapy-Oncolytics
- Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
- (2019) Nathan D. Trinklein et al. mAbs
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- The role of BAFF and APRIL in rheumatoid arthritis
- (2019) Arezoo G. Shabgah et al. JOURNAL OF CELLULAR PHYSIOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
- (2019) Yu-Tzu Tai et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
- (2019) Daniel Feinberg et al. CELLULAR IMMUNOLOGY
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- 2020PA Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion
- (2019) Z Li et al. ANNALS OF ONCOLOGY
- Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
- (2019) Dennis Cooper et al. BLOOD
- CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
- (2019) Jennifer Watkins-Yoon et al. BLOOD
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
- (2019) Caitlin L. Costello et al. BLOOD
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
- (2019) Lekha Mikkilineni et al. BLOOD
- Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Noopur S. Raje et al. BLOOD
- Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)
- (2019) Paul G. Richardson et al. BLOOD
- TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma
- (2019) Ben Buelow et al. BLOOD
- How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma
- (2019) Adam D Cohen et al. CLINICAL CANCER RESEARCH
- Exploring NKG2D and BCMA-CAR NK-92 for Adoptive Cellular Therapy to Multiple Myeloma
- (2019) Elena Maroto Martín et al. Clinical Lymphoma Myeloma & Leukemia
- AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment
- (2019) Shih-Feng Cho et al. Clinical Lymphoma Myeloma & Leukemia
- Off-the-shelf AlloCAR T™ cells targeting BCMA for the treatment of multiple myeloma
- (2019) Cesar Sommer et al. Clinical Lymphoma Myeloma & Leukemia
- Preclinical evaluation of CD8+ Anti-BCMA mRNA CAR T-Cells for control of multiple myeloma
- (2019) Liang Lin et al. Clinical Lymphoma Myeloma & Leukemia
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
- (2019) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Recent updates on CAR T clinical trials for multiple myeloma
- (2019) Quande Lin et al. Molecular Cancer
- Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality
- (2019) Mohit Sachdeva et al. Nature Communications
- Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma
- (2019) Frederick L. Locke et al. JAMA Oncology
- Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
- (2019) He Huang et al. Journal of Zhejiang University-SCIENCE B
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- CAR T-cell therapy: is it prime time in myeloma?
- (2019) Surbhi Sidana et al. Hematology-American Society of Hematology Education Program
- Bispecific antibodies in haematological malignancies
- (2018) Andreas Viardot et al. CANCER TREATMENT REVIEWS
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
- (2018) Danielle Mandikian et al. MOLECULAR CANCER THERAPEUTICS
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
- (2018) Z. Wu et al. PHARMACOLOGY & THERAPEUTICS
- Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
- (2018) De-Xiu Bu et al. Oncotarget
- A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
- (2018) Julien Valton et al. Scientific Reports
- Understanding the indirect DNA read-out specificity of I-CreI Meganuclease
- (2018) Jesús Prieto et al. Scientific Reports
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
- (2018) Jeremy S. Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting
- (2018) Laurie Baert et al. JOURNAL OF AUTOIMMUNITY
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
- (2018) Krista Kinneer et al. LEUKEMIA
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance
- (2018) Saori Suzuki et al. Scientific Reports
- FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
- (2017) Iulia Diaconu et al. MOLECULAR THERAPY
- T memory stem cells in health and disease
- (2017) Luca Gattinoni et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy
- (2017) Lisa Rosenbaum NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance
- (2017) Jing Pan et al. Oncology Letters
- Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
- (2017) Yariv Mazor et al. Scientific Reports
- Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy
- (2017) Anne-Sophie Gautron et al. Molecular Therapy-Nucleic Acids
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
- (2016) Noopur S. Raje et al. BRITISH JOURNAL OF HAEMATOLOGY
- Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways
- (2016) Xianjuan Shen et al. CELL BIOCHEMISTRY AND FUNCTION
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- (2016) E. Sanchez et al. CLINICAL CANCER RESEARCH
- Engineering a targeted delivery platform using Centyrins
- (2016) Shalom D. Goldberg et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload
- (2016) Arnaud C. Tiberghien et al. ACS Medicinal Chemistry Letters
- Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
- (2016) Marco Ruella et al. Current Hematologic Malignancy Reports
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Notch signaling: An emerging therapeutic target for cancer treatment
- (2015) Xun Yuan et al. CANCER LETTERS
- Blinatumomab: First Global Approval
- (2015) Mark Sanford DRUGS
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
- (2015) P J Hengeveld et al. Blood Cancer Journal
- A critical role for the NFkB pathway in multiple myeloma
- (2015) Oncotarget
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
- (2014) Tessa Gargett et al. Frontiers in Pharmacology
- γ-Secretase inhibitors and modulators
- (2013) Todd E. Golde et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Glycoproteomic Analysis of Antibodies
- (2013) Gerhild Zauner et al. MOLECULAR & CELLULAR PROTEOMICS
- The Role of CD19 and CD27 in the Diagnosis of Multiple Myeloma by Flow Cytometry
- (2012) Elisa Cannizzo et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Armed and accurate: engineering cytotoxic T cells for eradication of leukemia
- (2012) Marko Radic BMC BIOTECHNOLOGY
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells
- (2011) Jerome Thiery et al. NATURE IMMUNOLOGY
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
- (2009) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
- (2009) M. Griffioen et al. HAEMATOLOGICA
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
- (2009) Cornelia Haas et al. IMMUNOBIOLOGY
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
- (2008) Gema Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started